AbbVie (NYSE: ABBV) has entered a new collaboration with life sciences AI platform Valkai to apply purpose-built AI across targeted areas of clinical research, aiming to generate insights faster and support shorter development timelines.
Novo Nordisk HRS-1596 is the focus of a new exclusive license with Hengrui Pharma worth up to $2.6 billion, including $300 million upfront. The phase 1-ready GLP-1/GIP dual agonist has potential for once-weekly oral dosing.
Merck has entered into an exclusive global licensing agreement with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D inhibitor, in a transaction valued at up to $2.13 billion, including a $400 million upfront payment.
Charles River Laboratories launches its NGS-enabled rapid cell banking platform, cutting production timelines by 40% through automated rapid microbiological testing and in vitro characterization.
Charles River Laboratories has completed automation of its Endosafe Cartridge Technology manufacturing suite in Wilmington, Massachusetts, reporting double-digit gains in productivity, capacity and product consistency ahead of full operational scale-up in Q3 2026.
Eli Lilly will pay up to $2.875 billion to acquire Merida Biosciences, gaining a precision antibody-degradation platform led by Phase 1 candidate MER511 for Graves’ disease and thyroid eye disease.
Genentech, Roche’s US subsidiary, will invest approximately $750 million to build a new device fill-finish facility at its Hillsboro, Oregon campus, adding 250 manufacturing jobs and doubling the site’s size ahead of a 2031 commercial start.
The BioMarin Alesta Therapeutics acquisition secures lead oral asset ALE1 for $275M upfront plus milestones, expanding BioMarin’s rare disease skeletal pipeline.
AstraZeneca has officially stopped its Phase III eVOLVE-Lung02 trial evaluating volrustomig plus chemotherapy in first-line metastatic NSCLC following a recommendation from the Independent Data Monitoring Committee.
Thermo Fisher Scientific has completed the sale of its microbiology business to Astorg for approximately $1.075 billion in cash and a $50 million seller note. The divested unit, part of the Specialty Diagnostics segment, generated $645 million in 2025 revenue from antimicrobial susceptibility testing and culture media solutions.
